SG11201810576QA - New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents
New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- SG11201810576QA SG11201810576QA SG11201810576QA SG11201810576QA SG11201810576QA SG 11201810576Q A SG11201810576Q A SG 11201810576QA SG 11201810576Q A SG11201810576Q A SG 11201810576QA SG 11201810576Q A SG11201810576Q A SG 11201810576QA SG 11201810576Q A SG11201810576Q A SG 11201810576QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- hetero
- aryl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1655387A FR3052451B1 (fr) | 2016-06-10 | 2016-06-10 | Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR1663463A FR3061177B1 (fr) | 2016-12-28 | 2016-12-28 | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| PCT/EP2017/064062 WO2017212010A1 (en) | 2016-06-10 | 2017-06-09 | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810576QA true SG11201810576QA (en) | 2018-12-28 |
Family
ID=59021522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810576QA SG11201810576QA (en) | 2016-06-10 | 2017-06-09 | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
Country Status (42)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2938341T3 (es) | 2016-03-07 | 2023-04-10 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis B |
| FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CA3073986A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| GB201801562D0 (en) | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| UY38291A (es) * | 2018-07-05 | 2020-06-30 | Servier Lab | Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas |
| CN112955142A (zh) | 2018-09-21 | 2021-06-11 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| UY38423A (es) * | 2018-10-19 | 2021-02-26 | Servier Lab | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen |
| UY38483A (es) | 2018-11-21 | 2020-06-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| AU2019393162A1 (en) * | 2018-12-06 | 2021-06-17 | Almac Discovery Limited | Pharmaceutical compounds and their use as inhibitors of Ubiquitin Specific Protease 19 (USP19) |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CA3145592A1 (en) | 2019-07-03 | 2021-01-07 | Bayer Aktiengesellschaft | Substituted thiophene carboxamides and derivatives thereof as microbicides |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| BR112022010735A2 (pt) | 2019-12-20 | 2022-08-23 | Bayer Ag | Tiofeno carboxamidas substituídos, ácidos tiofeno carboxílicos e derivados dos mesmos |
| CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065494A1 (es) * | 2007-03-02 | 2009-06-10 | Schering Corp | Derivados de piperidina y metodos de uso de los mismos |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| JP2018504431A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン |
-
2017
- 2017-06-09 HU HUE17728567A patent/HUE048590T2/hu unknown
- 2017-06-09 UA UAA201900070A patent/UA123793C2/uk unknown
- 2017-06-09 CN CN201780047088.4A patent/CN109563094B/zh active Active
- 2017-06-09 GE GEAP201714982A patent/GEP20207161B/en unknown
- 2017-06-09 BR BR112018075284-3A patent/BR112018075284A2/pt not_active Application Discontinuation
- 2017-06-09 SG SG11201810576QA patent/SG11201810576QA/en unknown
- 2017-06-09 RS RS20200510A patent/RS60279B1/sr unknown
- 2017-06-09 MD MDE20190461T patent/MD3468971T2/ro unknown
- 2017-06-09 MY MYPI2018002417A patent/MY196328A/en unknown
- 2017-06-09 MA MA45223A patent/MA45223B1/fr unknown
- 2017-06-09 PE PE2018003132A patent/PE20220948A1/es unknown
- 2017-06-09 CA CA3027008A patent/CA3027008C/en active Active
- 2017-06-09 WO PCT/EP2017/064062 patent/WO2017212010A1/en unknown
- 2017-06-09 RU RU2018147424A patent/RU2742271C2/ru active
- 2017-06-09 CU CU2018000146A patent/CU20180146A7/es unknown
- 2017-06-09 MX MX2018015212A patent/MX2018015212A/es active IP Right Grant
- 2017-06-09 UY UY0001037289A patent/UY37289A/es unknown
- 2017-06-09 PT PT177285673T patent/PT3468971T/pt unknown
- 2017-06-09 LT LTEP17728567.3T patent/LT3468971T/lt unknown
- 2017-06-09 EP EP17728567.3A patent/EP3468971B1/en active Active
- 2017-06-09 TW TW106119243A patent/TWI647228B/zh not_active IP Right Cessation
- 2017-06-09 SI SI201730267T patent/SI3468971T1/sl unknown
- 2017-06-09 AU AU2017277732A patent/AU2017277732B2/en active Active
- 2017-06-09 ES ES17728567T patent/ES2778700T3/es active Active
- 2017-06-09 JP JP2018564752A patent/JP6985299B2/ja active Active
- 2017-06-09 US US16/306,941 patent/US10654849B2/en active Active
- 2017-06-09 PL PL17728567T patent/PL3468971T3/pl unknown
- 2017-06-09 DK DK17728567.3T patent/DK3468971T3/da active
- 2017-06-09 CR CR20180563A patent/CR20180563A/es unknown
- 2017-06-09 KR KR1020197000798A patent/KR102003532B1/ko active IP Right Grant
- 2017-06-09 TN TNP/2018/000395A patent/TN2018000395A1/en unknown
-
2018
- 2018-11-28 PH PH12018502516A patent/PH12018502516B1/en unknown
- 2018-11-29 SV SV2018005792A patent/SV2018005792A/es unknown
- 2018-12-03 DO DO2018000264A patent/DOP2018000264A/es unknown
- 2018-12-03 IL IL263455A patent/IL263455B/en active IP Right Grant
- 2018-12-04 CO CONC2018/0013141A patent/CO2018013141A2/es unknown
- 2018-12-04 EC ECSENADI201890046A patent/ECSP18090046A/es unknown
- 2018-12-04 CL CL2018003473A patent/CL2018003473A1/es unknown
- 2018-12-07 NI NI201800133A patent/NI201800133A/es unknown
- 2018-12-07 ZA ZA2018/08286A patent/ZA201808286B/en unknown
-
2020
- 2020-04-03 HR HRP20200556TT patent/HRP20200556T1/hr unknown
- 2020-05-18 CY CY20201100451T patent/CY1123069T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810576QA (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810629QA (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201805913QA (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201810430WA (en) | Heater assembly for an aerosol-generating system | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201910053YA (en) | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies |